Specifically, it was shown that RL2 treatment caused an upregulation of PINK1, BNIP3, and BNIP3L/NIX and the conversion of LC3 to LC3 II in breast cancer cells [21]. The gene discussed is BNIP3L; the disease is breast carcinoma.